CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2007-04-06): US FDA clears Cangene's anti-hepatitis B product


US FDA clears Cangene's anti-hepatitis B product

Last Updated: 2007-04-06 14:00:11 -0400 (Reuters Health)

WASHINGTON (Reuters) - Cangene Corp. won U.S. approval to promote its injectable HepaGam B product to prevent reinfection with the hepatitis B virus in certain liver transplant patients, health officials said on Friday.

HepaGam B is an immune globulin product derived from human plasma that can provide immunity against the hepatitis B virus, the Food and Drug Administration said.

Patients must receive injections at the time of liver transplant and throughout their lives, the FDA said. Liver transplant patients already exposed to the virus face a higher risk of reinfection because they have weakened immune systems, the FDA said.

HepaGam B was FDA-approved in January 2006 for preventing hepatitis B infection after various types of exposure.

Slide Library
Abstract Library
CME Dinner Meeting
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.